Feds fund $3.5M for Durham firm's yellow fever treatment

A Durham pharmaceutical company has received $3.5 million from a federal agency to support clinical trials for a drug to treat people with yellow fever. For BioCryst Pharmaceuticals, the latest funds from the National Institute of Allergy and Infectious Diseases (NIAID) for galidesivir brings development contract funding to a total of $43 million.   BioCryst saw success during its Phase 1 trials; healthy patients tolerated the drug and found it to be safe. In animal studies, galidesivir showed… (Source: bizjournals.com Health Care:Physician Practices headlines)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2plnXF8